文献速递青光眼

布林佐胺1%/溴莫尼定0.2%固定复方制剂24小时眼压控制的多中心随机试验

24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial.
PubMed 文献 · Ophthalmology · 2018-11-04

这项在美国16个中心开展的前瞻性双盲平行随机试验,纳入125例开角型青光眼或高眼压症患者,比较布林佐胺1%/溴莫尼定0.2%固定复方制剂(BBFC)与赋形剂每日3次治疗4周后的24小时眼压变化。结果显示BBFC组24小时平均眼压较赋形剂组显著降低,主要终点达标,日间各时间点及5个夜间时间点中的3个差异显著。

要点

  • BBFC每日3次治疗4周后24小时平均眼压较赋形剂显著降低,最小二乘均值差为-2.5 mmHg。
  • 日间眼压降幅显著(-3.4 mmHg),夜间降幅为-1.2 mmHg,P=0.053未达显著。
  • 不良事件频率两组相似,BBFC组常见眼充血、角膜擦伤和味觉障碍,与药品标签一致。

核心结论

  • BBFC每日3次治疗4周可显著优于赋形剂降低开角型青光眼或高眼压症患者的24小时平均眼压,达到主要终点。

研究设计与样本

  • 前瞻性、多中心、双盲、平行组临床试验,在美国16个学术和非学术中心开展。
  • 纳入125例年龄≥18岁、至少1眼基线平均眼压≥21且<28 mmHg的开角型青光眼或高眼压症受试者。
  • 受试者洗脱后测量基线24小时眼压,随机1:1接受BBFC或赋形剂每日3次(8 am、3 pm、10 pm)治疗4周,第4周重复24小时眼压测量。

主要发现

  • 125例随机化受试者中123例(98%)完成研究,BBFC组62例、赋形剂组61例,BBFC组无受试者中止研究。
  • 第4周BBFC组24小时平均眼压较基线变化显著优于赋形剂组,最小二乘均值差(95%CI)为-2.5(-3.3,-1.7)mmHg,P<0.001。
  • 日间眼压降幅差异为-3.4(-4.3,-2.6)mmHg,P<0.001;夜间降幅差异为-1.2(-2.3,0.0)mmHg,P=0.053。
  • BBFC组与赋形剂组在全部日间时间点及5个夜间时间点中的3个(10 pm、12 am、6 am)较基线变化差异显著(次要终点)。
  • 不良事件频率两组相似,BBFC组最常见不良事件为眼充血、角膜擦伤和味觉障碍,与药品标签描述一致。

关键数值与推荐

  • 主要终点为第4周24小时平均眼压较基线的变化,BBFC组显著优于赋形剂组(P<0.001)。
  • 日间(8 am-8 pm)坐位测量眼压降幅显著(P<0.001),夜间(10 pm-6 am)仰卧位测量降幅未达显著(P=0.053)。

临床怎么用

  • 对于开角型青光眼或高眼压症患者,BBFC每日3次可作为24小时眼压控制的一种固定复方制剂选择。
  • 用药时需关注眼充血、角膜擦伤和味觉障碍等不良事件,与药品标签一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the intraocular pressure (IOP)-lowering effect of fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) over a 24-hour period. DESIGN: Prospective, multicenter, double-masked, parallel-group clinical trial conducted at 16 academic and nonacademic sites in the United States. PARTICIPANTS: Subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) aged ≥18 years with mean baseline IOP measurements in at least 1 eye of ≥21 and <28 mmHg. METHODS: Duplicate mean pneumatonometer IOP measurements were collected every 2 hours over a 24-hour period in controlled light conditions in overnight facilities. Daytime (8 am-8 pm) and nocturnal (10 pm-6 am) IOP measurements were collected in a sitting or supine position, respectively. Baseline 24-hour IOP was measured in untreated subjects after a washout (up to 4 weeks) and eligibility phase. After the baseline visit, participants were randomized 1:1 to receive masked BBFC or vehicle, 1 drop 3 times daily (8 am, 3 pm, and 10 pm) for 4 weeks. At week 4, IOP measurements were repeated in both groups under the same conditions. MAIN OUTCOME MEASURE: Mean change from baseline in 24-hour IOP at week 4. RESULTS: Of 125 participants randomized, 123 (98%; BBFC, n = 62; vehicle, n = 61) completed the study. No subjects randomized to BBFC discontinued the study. At week 4, BBFC-treated eyes had significantly reduced mean 24-hour IOP vs. vehicle (least squares mean difference [95% confidence interval]: -2.5 [-3.3, -1.7]; P < 0.001); daytime (-3.4 [-4.3, -2.6]; P < 0.001) and nocturnal (-1.2 [-2.3, 0.0]; P = 0.053) reductions were observed. Mean change from baseline was significantly different between BBFC- and vehicle-treated eyes at all daytime points and 3 of 5 nocturnal time points (10 pm, 12 am, and 6 am; secondary end point). The frequency of adverse events was similar between treatment groups; in the BBFC arm, ocular hyperemia, corneal abrasion, and dysgeusia were the most frequently reported, consistent with events described in the drug label. CONCLUSIONS: This large, multicenter study of 24-hour IOP control with BBFC met its primary end point; BBFC demonstrated significantly superior 24-hour IOP-lowering efficacy versus vehicle after 4 weeks of 3-times-daily treatment in subjects with OAG or OHT.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Weinreb RN, Bacharach J, Fechtner RD, et al. 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial. Ophthalmology. 2018. PMID: 30403988. doi:10.1016/j.ophtha.2018.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。